ARKG stock sentiment todayARK Genomic Revolution ETF

A high-beta speculative vehicle suffering from persistent outflows, rising interest rate sensitivity, and a lack of profitability across its core holdings.

Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for ARKG. Not financial advice.

Market narrative is dominated by 'ARK fatigue' as Cathie Wood’s flagship strategies continue to underperform the broader tech rally. Investors are rotating out of speculative biotech and into profitable Big Tech or AI infrastructure.

• ·Concentration risk in volatile names like CRISPR and Exact Sciences
• ·Persistent outflows as retail investors lose patience with the 'five-year horizon'
• ·Negative momentum following the 3.17% daily drop

ARKG is comprised largely of pre-revenue or non-profitable companies. While the underlying genomics technology is revolutionary, the financial health of the fund is tied to cash-burn rates and the cost of capital.

• ·Negative P/E ratio for the majority of the portfolio
• ·High expense ratio (0.75%) compared to passive index funds
• ·Significant correlation to the 10-year Treasury yield

• ·Dilution risk from secondary offerings by constituent companies
• ·Regulatory hurdles (FDA) for gene-editing therapies
• ·High volatility/beta relative to the S&P 500

How direct competitors stack up against ARKG right now.

• NEUTRAL
  IBBiShares Biotechnology ETF

  SAFER — provides exposure to profitable blue-chip pharma like Amgen and Gilead, reducing downside risk compared to ARKG's speculative mix.

  See full analysis →
• NEUTRAL
  XBISPDR S&P Biotech ETF

  HOTTER — equal-weighted structure prevents single-stock blowups and captures M&A activity more efficiently than ARKG’s concentrated bets.

  See full analysis →
• COLD
  GNOMGlobal X Genomics & Biotechnology ETF

  NEUTRAL — trades at a lower expense ratio (0.50%) with a more disciplined indexing approach than ARKG’s active management.

  See full analysis →